drugset / Trial / NCT00650611

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

NCT00650611

Phase 2 Completed 63 enrolled Viatris Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of oral ziprasidone in children and teens with psychotic disorders

Timeline

Start
2003-12
Primary completion
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ziprasidone Small molecule 40 mg Oral
Comparator Ziprasidone Small molecule 80 mg Oral